VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$2.50 USD
+0.03 (1.21%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.51 +0.01 (0.40%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for VYNE Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 93 | 31 | 43 | 59 | 77 |
Receivables | 0 | 0 | 8 | 16 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 7 | 7 | 0 |
Other Current Assets | 3 | 7 | 5 | 5 | 1 |
Total Current Assets | 96 | 38 | 63 | 87 | 78 |
Net Property & Equipment | 0 | 0 | 0 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 4 | 4 | 0 |
Total Assets | 98 | 41 | 67 | 94 | 79 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 7 | 5 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 9 | 11 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 3 | 3 | 4 | 0 |
Total Current Liabilities | 8 | 9 | 18 | 21 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 33 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 10 | 18 | 56 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 780 | 694 | 688 | 604 | 253 |
Retained Earnings | -691 | -663 | -640 | -566 | -184 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 89 | 31 | 49 | 37 | 69 |
Total Liabilities & Shareholder's Equity | 98 | 41 | 67 | 94 | 79 |
Total Common Equity | 89 | 31 | 49 | 37 | 69 |
Shares Outstanding | 13.90 | 3.20 | 2.90 | 2.30 | 0.30 |
Book Value Per Share | 6.38 | 9.75 | 16.77 | 16.30 | 228.37 |
Fiscal Year End for VYNE Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 93 | 16 | 21 | 30 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 2 | 2 | 3 |
Total Current Assets | NA | 96 | 18 | 23 | 33 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 2 | 2 |
Total Assets | NA | 98 | 19 | 25 | 35 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 1 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 4 | 4 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 1 | 1 | 1 |
Total Current Liabilities | NA | 8 | 6 | 6 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 9 | 8 | 8 | 9 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 780 | 697 | 696 | 695 |
Retained Earnings | NA | -691 | -685 | -679 | -669 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 89 | 12 | 17 | 26 |
Total Liabilities & Shareholder's Equity | NA | 98 | 19 | 25 | 35 |
Total Common Equity | 0 | 89 | 12 | 17 | 26 |
Shares Outstanding | 14.10 | 13.90 | 3.30 | 3.20 | 3.20 |
Book Value Per Share | 0.00 | 6.38 | 3.49 | 5.40 | 8.26 |